摘要
随着肿瘤细胞生物学的进展，已研制出许多针对特异性分子靶向的治疗药物，而且在晚期非小细胞肺癌患者的一线和二线治疗中均已显示出较好的疗效，由于老年患者有着生理学、药理学等各方面的特点，对化疗耐受性差，而针对此类患者的分子靶向治疗具有重要临床价值。
With the development of tumor cell biology, many targeted therapy drugs that aim specifically to inhibit tumor growth have been developed. Application of targeted drugs as first-line and second-line therapy in patients with advanced non-small cell lung cancer （NSCLC）have acquired exciting curative effect. Molecular targeted therapy for old patients have important clinical values,because old patients have weak toleration to chemotherapy as a result of physical and pharmacological features.
出处
《国际肿瘤学杂志》
CAS
2009年第12期932-934,共3页
Journal of International Oncology
基金
浙江省医药卫生科学研究基金资助项目（2008A142）
关键词
老年人
癌
非小细胞肺
靶向治疗
Aged
Carcinoma,non-small-cell lung
Targeted therapy
